Tp53 and lrp1b co-wild predicts improved survival for patients with lusc receiving anti-pd-l1 immunotherapy

HIGHLIGHTS

• who: Jiangyong Yu et al. from the Department of Medical Oncology, Beijing Hospital, National Center of Gerontology have published the Article: TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy, in the Journal: (JOURNAL)
• what: The authors aimed to explore novel biomarker for immunotherapy and the potential mechanism. Next, the authors focused on TP53 and LRP1B genes. The authors explored the genomic profiles of LUSC in two cohorts of Geneplus and POPLAR/OAK.
• how: Copy-number variation (CNV) and whole genome doubling (WGD) data from . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.